Entrada Therapeutics, Inc. (TRDA) AI Stock Analysis

Entrada Therapeutics, Inc. is a biotechnology company dedicated to advancing therapies for neuromuscular diseases. Utilizing its endosomal escape vehicle (EEV) platform, the company creates therapeutic programs based on oligonucleotides, antibodies, and enzymes. Its lead product candidate, ENTR-601-44, is currently in preclinical trials targeting Duchenne muscular dystrophy and myotonic dystrophy type 1. Entrada Therapeutics also develops EEV-PMO-CAG for myotonic dystrophy type 1. Originally named CycloPorters, Inc., the company rebranded in October 2017. Established in 2016 and based in Boston, Massachusetts, the firm employs 152 people.

Entrada Therapeutics has experienced sharp revenue variability over recent fiscal periods. Revenue expanded from $25.3M in FY2022 to $129.0M in FY2023, before climbing to $210.8M in FY2024. However, FY2025 revenue fell 87.9% to $25.4M, resulting in a 3-year revenue CAGR of 0.2%. Profitability mirrored this pattern, posting net income of $65.6M in FY2024 with an operating margin of 22.3%, but dropping to a net income of -$143.8M and an operating margin of -613.7% in FY2025 as R&D expenses climbed to $142.3M. Over the trailing twelve months, revenue was $4.7M with an operating margin of -5007.0%, while the quarter ended June 30, 2026, saw revenue fall 53.9% year-over-year.

As of June 30, 2026, Entrada Therapeutics held $223.0M in cash and short-term investments against total debt of $48.5M, yielding net cash of $174.5M. The company maintains a current ratio of 10.89 and a debt-to-equity ratio of 0.21 on shareholders' equity of $233.4M. Operating cash flow in FY2025 was -$128.5M, while free cash flow stood at -$129.6M. Capital expenditures were $1.0M for FY2025, alongside $462,000 raised through share issuance, with the company's share count increasing 103.2% over 5 years.

Entrada Therapeutics trades at a price-to-sales multiple of 36.3x, significantly above the 4.1x median of its US-listed Healthcare peers. Its EV-to-EBITDA ratio is 1.6x compared to the peer group median of 12.0x, while its enterprise value sits at $78.6M against a market capitalization of $170.2M. Over the past year, TRDA shares fell 29.3%, lagging the S&P 500 benchmark return of 16.8%. The stock traded at $4.37 as of October 16, 2026, which is 51.7% below its 200-day average.

Wall Street coverage includes 7 Strong Buy ratings and 1 Hold rating, with no Buy, Sell, or Strong Sell recommendations. The mean price target is $19.00, representing a 334.8% premium over the last close of $4.37. For the fiscal year ending December 31, 2026, analysts expect revenue of $12.2M and an EPS of -$3.79. For the next fiscal year, 6 analysts project revenue to increase 87.9% to $22.9M with an EPS of -$3.01. Entrada Therapeutics has beaten EPS estimates in 3 of the last 4 quarters, and its next earnings date is November 5, 2026.

This page is an AI-written research summary of Entrada Therapeutics, Inc. (TRDA). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: TRDA income statement, TRDA balance sheet, TRDA key metrics, TRDA analyst forecast, TRDA chart. See the TRDA stock overview for the latest quote and news.